Vanta Bioscience
23.23
-1.22(-4.99%)
Market Cap₹16.53 Cr
PE Ratio-1.31
IndustryHealthcare
Company Performance:
1D-4.99%
1M+42.95%
6M-1.90%
1Y-6.33%
5Y-86.49%
View Company Insightsright
More news about Vanta Bioscience
01Aug 25
Vanta Bioscience Reports Significant Losses for FY2025 Amid Revenue Decline
Vanta Bioscience Limited, a preclinical contract research organization, reported a substantial net loss for FY2025. Standalone net loss was Rs 265.95 lakh, compared to a profit of Rs 5.11 lakh in the previous year. Revenue from operations declined by 86.80% to Rs 112.74 lakh. Consolidated results showed a net loss of Rs 477.49 lakh, with revenue falling by 79.80% to Rs 196.36 lakh. The company faced operational challenges, including delays in consolidating financial results due to late receipt of accounts from an associate company. Despite financial difficulties, total assets increased by 2.52% to Rs 52.90 crore, while current liabilities rose by 39.22% to Rs 14.20 crore.
 no imag found
Vanta Bioscience
23.23
-1.22
(-4.99%)
1 Year Returns:-6.33%
Industry Peers
Syngene International
442.00
(-4.00%)
Indegene
521.55
(+0.51%)
Suven Life Sciences
279.34
(+4.56%)
Vimta Labs
469.70
(+2.85%)
Take Solutions
30.80
(-0.42%)
Bilcare
62.20
(-0.43%)
Adeshwar Meditex
18.41
(0.0%)
Vanta Bioscience
23.23
(-4.99%)